Read + Share
Fan L, Wang ZH, Ma LX, Wu SY, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer
(FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol 2024 Jan 8:S1470-2045(23)00579.
PMID: 38211606
|
 |
|
Fan L, Wang ZH, Ma LX, Wu SY, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer
(FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol 2024 Jan 8:S1470-2045(23)00579.
PMID: 38211606
|
|
|
|